GERMANTOWN, Md., June 30, 2016 /PRNewswire/ -- Intrexon
Corporation (NYSE: XON), a leader in synthetic biology, today
announced the appointment of Fred
Hassan to its Board of Directors, effective June 30. Mr. Hassan is currently a Partner
and Managing Director at Warburg Pincus LLC, a global private
equity firm.
Mr. Hassan has been Partner and Managing Director at Warburg
Pincus LLC, a global private equity investment institution, since
2011 and, prior to that, served as Senior Advisor from 2009 to
2010. Previously, Mr. Hassan served as Chairman and Chief
Executive Officer of Schering-Plough from 2003 to 2009.
Before assuming these roles, from 2001 to 2003 Mr. Hassan was
Chairman and Chief Executive Officer of Pharmacia Corporation, a
company formed as a result of the merger of Monsanto Company and
Pharmacia & Upjohn, Inc. He joined Pharmacia &
Upjohn, Inc. as Chief Executive Officer in 1997. Mr. Hassan
previously held leadership positions with Wyeth serving as
Executive Vice President, and was a member of the Board from 1995
to 1997. Earlier in his career, he spent a significant tenure
with Sandoz Pharmaceuticals and headed the company's U.S.
pharmaceuticals business.
Mr. Hassan has also been a director of Time Warner Inc. since
October 2009 and director of Amgen,
Inc. since July 2015. In the course of his career, he has
held numerous directorships, including those at Avon Products, Inc.
from 1999 to 2013, Bausch & Lomb from 2010 until its
acquisition by Valeant Pharmaceuticals International, Inc. in 2013,
and Valeant Pharmaceuticals International, Inc. from 2013 to
2014. Mr. Hassan has chaired notable pharmaceutical industry
organizations including The Pharmaceutical Research and
Manufacturers of America (PhRMA) and The International Federation
of Pharmaceutical Manufacturers Associations (IFPMA) and is also a
member of The Business Council. He received B.S. degree in
chemical engineering from the Imperial College of Science and
Technology at the University of London and an M.B.A. from Harvard Business School.
On Mr. Hassan's joining the Board, Randal J. Kirk, Chairman and Chief Executive
Officer of Intrexon, said, "Fred is a legend in our industry and
well known for the breadth of his experience and intellect, his
leadership and analytical skills and his mentorship of many of the
most successful life science leaders who are active today. On
behalf of our Board of Directors, I welcome Fred as we look forward
to his contributions and insights."
Mr. Hassan commented, "Watching how Intrexon has grown into a
leading player in the world of synthetic biology, which has vast,
expanding implications across a number of industries, has been
exciting to see. I am pleased to have the opportunity to join
Intrexon's Board and provide guidance to the Company to assist in
the ongoing development of its existing and future collaborations,
and help realize its significant potential."
About Intrexon Corporation
Intrexon Corporation (NYSE:
XON) is Powering the Bioindustrial Revolution with Better DNA™ to
create biologically-based products that improve the quality of life
and the health of the planet. The Company's integrated technology
suite provides its partners across diverse markets with
industrial-scale design and development of complex biological
systems delivering unprecedented control, quality, function, and
performance of living cells. We call our synthetic biology approach
Better DNA®, and we invite you to discover more at
www.dna.com or follow us on Twitter at @Intrexon.
Trademarks
Intrexon, Powering the Bioindustrial
Revolution with Better DNA, and Better DNA are trademarks of
Intrexon and/or its affiliates. Other names may be trademarks of
their respective owners.
Safe Harbor Statement
Some of the statements made in
this press release are forward-looking statements. These
forward-looking statements are based upon our current expectations
and projections about future events and generally relate to our
plans, objectives and expectations for the development of our
business. Although management believes that the plans and
objectives reflected in or suggested by these forward-looking
statements are reasonable, all forward-looking statements involve
risks and uncertainties and actual future results may be materially
different from the plans, objectives and expectations expressed in
this press release.
For more information regarding Intrexon Corporation,
contact:
Investor Contact:
Christopher Basta
Vice President, Investor Relations
Tel: +1 (561) 410-7052
investors@intrexon.com
Corporate Contact:
Marie
Rossi, Ph.D.
Senior Manager, Technical Communications
Tel: +1 (301) 556-9850
publicrelations@intrexon.com
Logo -
http://photos.prnewswire.com/prnh/20130919/NY83283LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/intrexon-appoints-fred-hassan-distinguished-life-sciences-executive-to-board-of-directors-300292932.html
SOURCE Intrexon Corporation